Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | NA | High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.08 | 1.72 |
NAV | ₹20.27 | ₹75.82 |
Fund Started | 22 Jan 2015 | 16 Feb 2004 |
Fund Size | ₹154.69 Cr | ₹3219.98 Cr |
Exit Load | - | Exit load for units in excess of 30% of the investment,1% will be charged for redemption within 1 year |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 5.62% | 8.46% |
3 Year | 10.28% | 10.82% |
5 Year | 7.27% | 10.34% |
1 Year
3 Year
5 Year
Equity | 21.09% | 22.15% |
Cash | 2.95% | 5.12% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
ICICI Bank Ltd. | 2.80% |
HDFC Bank Ltd. | 2.39% |
Reliance Industries Ltd. | 1.75% |
State Bank of India | 1.59% |
Larsen & Toubro Ltd. | 1.13% |
Infosys Ltd. | 1.04% |
NTPC Ltd. | 1.03% |
Axis Bank Ltd. | 1.01% |
Mahindra & Mahindra Ltd. | 0.82% |
Dixon Technologies (India) Ltd. | 0.73% |
Name | Assets |
---|---|
ICICI Bank Ltd. | 1.67% |
SBI Life Insurance Company Ltd. | 1.36% |
Maruti Suzuki India Ltd. | 1.13% |
HDFC Bank Ltd. | 1.06% |
Sun Pharmaceutical Industries Ltd. | 1.06% |
NTPC Ltd. | 0.94% |
Axis Bank Ltd. | 0.93% |
Bharti Airtel Ltd. | 0.87% |
HDFC Life Insurance Co Ltd. | 0.85% |
Gland Pharma Ltd. | 0.79% |
Name | Akshay Sharma | Ritesh Lunawat |
Start Date | 01 Dec 2022 | 28 Dec 2020 |
Name
Start Date
Description | The scheme seeks to provide capital appreciation and consistent income to the investors which will be in line with their retirement goals by investing in a mix of securities comprising of equity, equity related instruments and fixed income securities. | The scheme seeks to generate long-term capital appreciation by investments in money market and debt instruments. |
Launch Date | 22 Jan 2015 | 16 Feb 2004 |
Description
Launch Date